HK1192725A1 - 型糖尿病患者中低血糖症的預防 - Google Patents

型糖尿病患者中低血糖症的預防

Info

Publication number
HK1192725A1
HK1192725A1 HK14105960.9A HK14105960A HK1192725A1 HK 1192725 A1 HK1192725 A1 HK 1192725A1 HK 14105960 A HK14105960 A HK 14105960A HK 1192725 A1 HK1192725 A1 HK 1192725A1
Authority
HK
Hong Kong
Prior art keywords
hypoglycaemia
prevention
diabetes mellitus
mellitus type
type patients
Prior art date
Application number
HK14105960.9A
Other languages
English (en)
Inventor
Gabor Boka
Louise Silvestre
Patrick Miossec
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44504331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1192725(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of HK1192725A1 publication Critical patent/HK1192725A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
HK14105960.9A 2011-03-29 2014-06-23 型糖尿病患者中低血糖症的預防 HK1192725A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11160270 2011-03-29
PCT/EP2012/055660 WO2012130955A1 (en) 2011-03-29 2012-03-29 Prevention of hypoglycaemia in diabetes mellitus type 2 patients

Publications (1)

Publication Number Publication Date
HK1192725A1 true HK1192725A1 (zh) 2014-08-29

Family

ID=44504331

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14105960.9A HK1192725A1 (zh) 2011-03-29 2014-06-23 型糖尿病患者中低血糖症的預防

Country Status (20)

Country Link
US (2) US20120277147A1 (zh)
EP (1) EP2691109B1 (zh)
JP (1) JP6410600B2 (zh)
KR (1) KR20140033030A (zh)
CN (1) CN103582491B (zh)
AU (1) AU2012234180B2 (zh)
BR (1) BR112013024973B1 (zh)
CA (1) CA2830811A1 (zh)
CY (1) CY1116799T1 (zh)
DK (1) DK2691109T3 (zh)
ES (1) ES2549955T3 (zh)
HK (1) HK1192725A1 (zh)
HR (1) HRP20151087T1 (zh)
HU (1) HUE025716T2 (zh)
MX (1) MX336657B (zh)
PL (1) PL2691109T3 (zh)
PT (1) PT2691109E (zh)
RU (1) RU2583134C2 (zh)
SI (1) SI2691109T1 (zh)
WO (1) WO2012130955A1 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101939557B1 (ko) 2008-10-17 2019-01-17 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물
CN107308442B (zh) 2009-11-13 2022-10-18 赛诺菲-安万特德国有限公司 包含glp-1激动剂、胰岛素和甲硫氨酸的药物组合物
PT3345593T (pt) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
LT2611458T (lt) 2010-08-30 2016-12-27 Sanofi-Aventis Deutschland Gmbh Ave0010 panaudojimas gaminant vaistą, skirtą 2 tipo cukrinio diabeto gydymui
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
MX370264B (es) 2011-08-29 2019-12-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
BR112016013832A2 (pt) 2014-01-09 2017-08-08 Sanofi Sa Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico
JP6735674B2 (ja) 2014-01-09 2020-08-05 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
EP3091995B1 (en) 2014-01-09 2024-03-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
SI3229828T1 (sl) 2014-12-12 2023-06-30 Sanofi-Aventis Deutschland Gmbh Formulacija s fiksnim razmerjem inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
WO2020112253A2 (en) * 2018-10-16 2020-06-04 The Board Of Regents Of The University Of Oklahoma Uses of glucagon-like peptide-1 receptor agonists for treating trauma-induced hearing loss

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
BR0015294A (pt) * 1999-11-03 2003-07-15 Bristol Myers Squibb Co Método para tratamento da diabetes
CN1413582A (zh) * 2002-11-29 2003-04-30 贵州圣济堂制药有限公司 盐酸二甲双胍肠溶片及其制备方法
ATE539743T1 (de) * 2005-06-27 2012-01-15 Newtree Co Ltd Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan
BRPI0616195A2 (pt) * 2005-09-20 2011-06-14 Novartis Ag uso de um inibidor de dpp-iv para reduzir eventos hipoglicÊmicos
KR101939557B1 (ko) * 2008-10-17 2019-01-17 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 ｇｌｐ－1 효능제의 병용물

Also Published As

Publication number Publication date
EP2691109B1 (en) 2015-07-15
CN103582491A (zh) 2014-02-12
US20180000902A1 (en) 2018-01-04
DK2691109T3 (en) 2015-10-19
EP2691109A1 (en) 2014-02-05
SI2691109T1 (sl) 2015-11-30
BR112013024973A2 (pt) 2016-08-30
AU2012234180A1 (en) 2013-10-17
CY1116799T1 (el) 2017-03-15
MX336657B (es) 2016-01-27
HRP20151087T1 (hr) 2015-11-20
RU2013148014A (ru) 2015-05-10
PT2691109E (pt) 2015-10-30
AU2012234180B2 (en) 2017-02-16
JP6410600B2 (ja) 2018-10-24
HUE025716T2 (en) 2016-04-28
KR20140033030A (ko) 2014-03-17
US20120277147A1 (en) 2012-11-01
WO2012130955A1 (en) 2012-10-04
MX2013011174A (es) 2013-11-01
ES2549955T3 (es) 2015-11-03
PL2691109T3 (pl) 2015-12-31
RU2583134C2 (ru) 2016-05-10
CA2830811A1 (en) 2012-10-04
CN103582491B (zh) 2016-12-07
BR112013024973B1 (pt) 2022-06-07
JP2014514289A (ja) 2014-06-19

Similar Documents

Publication Publication Date Title
HK1192725A1 (zh) 型糖尿病患者中低血糖症的預防
ZA201403795B (en) Formulations for the treatment of diabetes
IL222778A0 (en) Diabetes therapy
HK1196267A1 (zh) 用於 型糖尿病患者中的血糖控制的藥物組合
PL2779973T3 (pl) Interfejs pacjenta ze zmienną aplanacją
IL228771A0 (en) Glycoside history and their use in the treatment of diabetes
IL223289A0 (en) Treatment of type 2 diabetes
HK1206292A1 (zh) 藥物給藥
HK1201209A1 (zh) 糖尿病的治療藥
EP2774917A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES
HRP20180011T1 (hr) Spojevi za uporabu u liječenju filariaza
HK1257401A1 (zh) 用於治療糖尿病和相關病症的方法和組合物
IL232239A0 (en) Medical use
GB201117172D0 (en) Diabetes
EP2455090A4 (en) MEANS TO INHIBIT THE INCREASE OF THE POSTPRANDIAL BLOOD INSULIN MIRROR
EP2687212A4 (en) DRUG AGENT
PL3097920T3 (pl) Kompozycja medyczna zawierająca ekstrakt stauntonia hexaphylla
PL2536400T3 (pl) Lek zawierający miramistin
HK1202819A1 (zh) 型和 型糖尿病的治療
EP2617726A4 (en) DIABETES THERAPEUTIC
HK1196953A1 (zh) 用於治療糖尿病的製劑
PT2717872T (pt) Combinação sinérgica para o tratamento da diabetes mellitus tipo 2
AU2011902031A0 (en) Improvements in medical treatment
GB201104632D0 (en) Use of medicament
GB201104872D0 (en) New compounds and medical uses

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230331